Waldencast CEO Michel Brousset Sells 264,294 RSUs

What Happened
Michel Brousset, CEO of Waldencast plc (WALD), had 264,294 restricted stock units (RSUs) disposed of to the issuer on July 30, 2026. The issuer repurchased the RSUs at $2.00 per unit for a total cash value of $528,588. The filing reports this as a derivative disposition (transaction code D), not an open-market sale.

Key Details

• Transaction date: July 30, 2026; Price: $2.00 per RSU; Total value: $528,588.
• Transaction type: Disposition to issuer (D) — issuer repurchased outstanding RSUs (derivative).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote highlights:
  • F1: Each RSU represents a contingent right to one Class A ordinary share or equivalent cash.
  • F2: The 264,294 RSUs were repurchased by the issuer in connection with Waldencast’s sale of its Obagi Medical business; effective that date Brousset transitioned to lead Obagi Medical.
  • F3: Brousset was originally granted 396,440 RSUs on Oct 30, 2024 with a three-year vesting schedule (132,146 on 10/1/25; 132,147 on 10/1/26; 132,147 on 10/1/27).
• No late filing indication in the provided data.

Context
This was a company repurchase of RSUs tied to the corporate transaction (sale of Obagi Medical) rather than a market sale by the insider. For retail investors, such repurchases reflect settlement of equity awards in connection with corporate reorganizations or departures and are different from open-market insider sales as a signal of sentiment.